Phase III Clinical Trial of Fentanyl Transdarmal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics - Full Text View

Sponsored by:	Janssen Pharmaceutical K.K.
Information provided by:	Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier:	NCT00216684

Purpose

The purpose of this study is to verify the effectiveness, and safety in Japanese patients with chronic intractable pain after 4-week medication of fentanyl transdermal matrix patches containing either 12.5 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, or 100 mcg/hr, who have been switched from existing formulations, such as codeine, morphine hydrochloride, or fentanyl injectable. Furthermore, the safety and effectiveness of long term treatment such as 48 weeks are to be assessed, if possible.

Condition	Intervention	Phase
Pain, Intractable	Drug: fentanyl	Phase III

Drug Information available for: Fentanyl Citrate Fentanyl Codeine Codeine phosphate Morphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	An Open Label Study to Confirm the Effectiveness, and Safety of Fentanyl Transdermal Matrix Patch in Japanese Patients With Chronic Intractable Pain Who Has Prior Therapy of Codeine, Morphine Hydrochloride, or Fentanyl Injectable Preparations.

Further study details as provided by Janssen Pharmaceutical K.K.:

Primary Outcome Measures:

Patient's global assessments of pain on the completion day of Treatment period 1

Secondary Outcome Measures:

Physician's global assessments, pain intensity (Visual Analog Scale: VAS), pain intensity (categorical scale), total pain duration per day, and dose of rescue medication, Adverse events, laboratory values, and vital signs. Pharmacokinetics

Estimated Enrollment:	120
Study Start Date:	April 2005
Estimated Study Completion Date:	September 2006

Detailed Description:

Fentanyl transdermal matrix patch is a narcotic analgesic agent. Compared with the existing reservoir-type Durotep® Patch, fentanyl transdermal matrix patch is not liable to leakage of drug solution and does not contain alcohol, which becomes a cause of skin irritation. Also this new formulation has become available in a smaller dose of 12.5mg/hr while the smallest Durotep® Patch is 25mg/hr. While Durotep® Patch is currently indicated only for cancer pain in Japan, this clinical trial was planned to assess effectiveness, and safety of fentanyl transdermal matrix patch in Japanese patients with chronic intractable pain receiving codeine, morphine hydrochloride, or fentanyl injectable formulations. After pre-treatment period for seven to fourteen days for evaluating the eligibility of the patients for the study, patients will be treated for 4 weeks as Treatment period 1 and 48 weeks as Treatment period 2 followed by 3-day post-treatment observation period. One patch can be used for 72 hours, which is the same as the existing Patch.

Starting from the first day of treatment, fentanyl will be applied to the chest, the upper arm or other appropriate site, which will be replaced with a new patch every three days (ca. 72 hr). Starting dose should be between 12.5 mcg/hr and 75 mcg/hr, depending on the prior opioid dose.

Eligibility

Ages Eligible for Study:	20 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with chronic intarctable pain receiving any of the following treatments :(1)Codeine phosphate, (2)Morphine hydrochloride preparations equivalent to less than 315 mg/day of oral morphine, (3)Fentanyl citrate injectable solution equivalent to less than 0.3 mg/day - Patients with chronic intractable pain in whom lesions causative of pain cannot be removed or treated, or in whom pain has been persisting for at least 12 weeks despite of the existing medication
Patients may be hospitalized during application of the initial transdermal dose of fentanyl transdermal matrix patches (patients may be ambulatory when the study starts)

Exclusion Criteria:

Patients with respiratory dysfunction such as chronic pulmonary disease
Patients with asthma
Patients with bradyarrhythmia
Patients with concurrent liver and/or kidney dysfunction according to the latest laboratory test values within 14 days before the start of the pre-treatment observation period
Patients with organic brain disorder such as elevated intracranial pressure, disturbance of consciousness/coma, or brain tumor
Patients with any psychoneurologic complication and judged incapable of self assessment
Patients with or with a history of drug dependency or narcotic abuse
Patients with a history of hypersensitivity to fentanyl or any other opioid analgesic

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00216684

Sponsors and Collaborators

Janssen Pharmaceutical K.K.

Investigators

Study Director:

Janssen Pharmaceutical K.K. Clinical Trial

Janssen Pharmaceutical K.K.

More Information

Study ID Numbers:	CR004879
Study First Received:	September 13, 2005
Last Updated:	October 19, 2007
ClinicalTrials.gov Identifier:	NCT00216684
Health Authority:	Japan: Japan Pharmaceuticals And Medical Devices Evaluation Center

Keywords provided by Janssen Pharmaceutical K.K.:

Fentanyl, Chronic intractable pain, Japanese patients

Study placed in the following topic categories:

Pain, Intractable
Morphine
Signs and Symptoms
Fentanyl

Neurologic Manifestations
Pain
Codeine

Additional relevant MeSH terms:

Anesthetics, Intravenous
Nervous System Diseases
Physiological Effects of Drugs
Anesthetics
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Adjuvants, Anesthesia

Sensory System Agents
Anesthetics, General
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 14, 2009